Current Report Filing (8-k)
05 Agosto 2020 - 5:22PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 4, 2020
ITOCO
INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
333-151840
|
45-0557179
|
(State
or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification No.)
|
|
880-50
West Liberty Street
Reno,
NV
|
89501
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code (905) 829-5000
N/A
(Former name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
¨
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Section
8 - Other Events
Item
8.01 Other Events.
On August 4, 2020, Itoco Inc. (the “Company”) announced it will be bringing advanced molecular diagnostic
technologies and a patented DNA test kit platform to market via a co-development agreement with ACGT DNA Technologies
(“ACGT”). The Company will have various rights to market the technologies, initially to the state of New York,
Canada, Mexico, and Germany. Other territories may be added to the arrangement over time. Profits from these territories
shall be split equally with ACGT net of expenses. Additionally, the Company and ACGT shall establish a laboratory to
co-develop products that can be used on the platform. The ACGT DNA Test Kit platform uses patented proprietary DNA and RNA
analysis techniques to detect viruses and other disease-causing organisms. Test times have the potential to be significantly
faster than current widely used technology. The system is at the advanced prototype stage and is available for demonstrative
purposes.
A copy of the press release announcing the
foregoing description is attached hereto as Exhibit 99.1.
Change in SIC code
In June 2020, the
Company’s SIC code was changed to 8731 - Commercial Physical & Biological Research to reflect the change in
business direction to the Biotechnology sector.
Section
9 – Financial Statement and Exhibits
Item 9.01 Financial Statements and Exhibits.
|
Exhibit
No.
|
|
Document
|
|
Location
|
|
99.1
|
|
Press release announcing ITOCO to Bring Molecular Diagnostic
Technologies and a DNA Test Kit Platform to Market, dated August 4, 2020
|
|
Filed Herewith.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
ITOCO INC.
(Registrant)
|
|
Date:
August 5, 2020
|
By:
/s/ Michael Anthony Paul
Michael
Anthony Paul
Chief Executive Officer
|
Itoco (PK) (USOTC:ITMC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Itoco (PK) (USOTC:ITMC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
